Cargando…
Incidence in pharmacoepidemiology—Basic definitions and types of misclassification
The definition of a new case is a vital step in incidence studies in both epidemiology and pharmacoepidemiology, although with significant differences in methodology between the fields. We define and apply a framework for two different types of new cases of drug use, first‐ever and recurrent, and sh...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320840/ https://www.ncbi.nlm.nih.gov/pubmed/35357769 http://dx.doi.org/10.1111/bcpt.13727 |
_version_ | 1784755890591629312 |
---|---|
author | Hoffmann, Mikael Støvring, Henrik |
author_facet | Hoffmann, Mikael Støvring, Henrik |
author_sort | Hoffmann, Mikael |
collection | PubMed |
description | The definition of a new case is a vital step in incidence studies in both epidemiology and pharmacoepidemiology, although with significant differences in methodology between the fields. We define and apply a framework for two different types of new cases of drug use, first‐ever and recurrent, and show how the associated misclassifications related to length of run‐in period can be expressed by the positive predictive value (PPV). In the study, we consider individual‐level dispensations of statins 2006–2019 for 1,017,058 individuals with at least one dispensation in 2019 in Sweden. The incidence proportion for statins for both sexes of all ages in Sweden 2019 varied from 17.4/1000 with a run‐in of 8 months, 9.45/1000 with 5 years and 8.4/1000 with 10 years. The PPV was 49% with 8 months and 89% for 5 years using 10 years as gold standard. We conclude that the interpretation of incidence and thus the selection of an appropriate run‐in period, in pharmacoepidemiology, depends on whether first‐ever use, recurrent treatment or both together (new cases) is the focus of the research question studied. At least five different misclassifications can be introduced depending on how incidence is defined. |
format | Online Article Text |
id | pubmed-9320840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93208402022-07-30 Incidence in pharmacoepidemiology—Basic definitions and types of misclassification Hoffmann, Mikael Støvring, Henrik Basic Clin Pharmacol Toxicol Original Articles The definition of a new case is a vital step in incidence studies in both epidemiology and pharmacoepidemiology, although with significant differences in methodology between the fields. We define and apply a framework for two different types of new cases of drug use, first‐ever and recurrent, and show how the associated misclassifications related to length of run‐in period can be expressed by the positive predictive value (PPV). In the study, we consider individual‐level dispensations of statins 2006–2019 for 1,017,058 individuals with at least one dispensation in 2019 in Sweden. The incidence proportion for statins for both sexes of all ages in Sweden 2019 varied from 17.4/1000 with a run‐in of 8 months, 9.45/1000 with 5 years and 8.4/1000 with 10 years. The PPV was 49% with 8 months and 89% for 5 years using 10 years as gold standard. We conclude that the interpretation of incidence and thus the selection of an appropriate run‐in period, in pharmacoepidemiology, depends on whether first‐ever use, recurrent treatment or both together (new cases) is the focus of the research question studied. At least five different misclassifications can be introduced depending on how incidence is defined. John Wiley and Sons Inc. 2022-04-13 2022-06 /pmc/articles/PMC9320840/ /pubmed/35357769 http://dx.doi.org/10.1111/bcpt.13727 Text en © 2022 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Hoffmann, Mikael Støvring, Henrik Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title | Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title_full | Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title_fullStr | Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title_full_unstemmed | Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title_short | Incidence in pharmacoepidemiology—Basic definitions and types of misclassification |
title_sort | incidence in pharmacoepidemiology—basic definitions and types of misclassification |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320840/ https://www.ncbi.nlm.nih.gov/pubmed/35357769 http://dx.doi.org/10.1111/bcpt.13727 |
work_keys_str_mv | AT hoffmannmikael incidenceinpharmacoepidemiologybasicdefinitionsandtypesofmisclassification AT støvringhenrik incidenceinpharmacoepidemiologybasicdefinitionsandtypesofmisclassification |